Overview
This is a multi-center, open-label, Phase 1/2 study of ZG005 for the treatment of subjects with advanced solid tumors, and consists of three stages: dose escalation and confirmation of MTD/recommended dose.
Eligibility
Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
- Life expectancy ≥ 3 months;
- Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Exclusion Criteria:
- Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
- Any other malignancy within 5 years.